Bavarian Nordic to Host First Half 2012 Results Conference Call

Bavarian Nordic to Host First Half 2012 Results Conference Call

ID: 175972

(Thomson Reuters ONE) -


KVISTGAARD, Denmark - August 20, 2012 - Bavarian Nordic A/S (OMX:  BAVA) will
announce its 2012 first half results on Tuesday, August 28, 2012.

The company will host a conference call at 2:00 pm CET (8:00 am EDT) on the same
day. Anders Hedegaard, President and CEO, will give a short presentation
followed by a Q&A session. Additional participants from Bavarian Nordic are Paul
Chaplin, Executive Vice President and Division President Infectious Diseases,
Reiner Laus, Executive Vice President and Division President Cancer Vaccines,
Ole Larsen, Executive Vice President and CFO and Rolf Sass Sørensen, Vice
President Investor Relations.

Dial-in numbers for the conference call are:  UK: +44 (0)207 1620 177. USA:
+1 334 323 6201. Denmark: +45 32 71 46 07. The participant code is 921026.

For additional details please visit http://www.bavarian-nordic.com/q2 where also
the accompanying presentation will be available in advance of the conference
call.

A recording of the conference call will be available from the company's website
during the same day.

Contact

Rolf Sass Sørensen, Vice President Investor Relations & Communications

E-mail: investor(at)bavarian-nordic.com

Phone: +45 33 26 83 83

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer




Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com.




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1634032]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Vacon Oyj: SHARE REPURCHASE 20.8.2012 DGAP-News: Micron Technology Appoints John Waite to Vice President of Global Supply Chain
Bereitgestellt von Benutzer: hugin
Datum: 20.08.2012 - 18:00 Uhr
Sprache: Deutsch
News-ID 175972
Anzahl Zeichen: 3072

contact information:
Town:

Kvistgård



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 278 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Bavarian Nordic to Host First Half 2012 Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von

Bavarian Nordic A/S (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Bavarian Nordic A/S



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z